| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6157036 | American Journal of Kidney Diseases | 2016 | 9 Pages |
Abstract
Simvastatin plus ezetimibe prevented atherosclerotic events in SHARP, but other less costly statin regimens are likely to be more cost-effective for reducing cardiovascular risk in CKD.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Borislava DPhil, Iryna DPhil, William MD, Jingky PhD, Seamus MSc, Jonathan PhD, Christina FRCP, Richard DM, FRCP, Alan PhD, Jonathan PhD, Alastair PhD, Rory FRS, Martin J. PhD, FRCP, Colin FRCP,